Danazol and Hemophilia

William E. Hathaway, MD
JAMA. 1985;253(8):1167. doi:10.1001/jama.1985.03350320091025.
Text Size: A A A
Published online

Danazol is a 2,3-isoxazol derivative of 17 α-ethinyl testosterone; it is known to be an anabolic steroid with mild androgenic activity. The administration of the drug is associated with raised plasma levels of several proteins including prealbumin, haptoglobulin, transferrin, antithrombin III, prothrombin, plasminogen, α1-antitrypsin, and Cl esterase inhibitor.1,2 Last year Gralnick and Rick1 reported evidence that danazol was associated with increased levels of factor VIIIc and factor IX and decreased transfusion requirements in patients with hemophilia. Subsequent studies by Gralnick and associates4 as well as other studies by Garewal et al5 are reported in this issue of The Journal and form the basis for this commentary.

The readers of the aforementioned articles are faced with a dilemma in judging the usefulness of danazol in management of hemophilia patients. Gralnick et al report on three of their initial patients plus eight French patients with hemophilia A.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.